149 related articles for article (PubMed ID: 32873573)
21. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
23. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Isla D; De Las Peñas R; Insa A; Marsé R; Martínez-Banaclocha N; Mut P; Morán T; Sala MÁ; Massuti B; Ortega AL; Jurado JM; Gómez-Codina J; Diz P; Artal Á; Gutiérrez V; Vázquez MF; Viñolas N; Maestu I; Camps C; Álvarez R; de Mon Soto MÁ; Ponce S; Provencio M
Lung Cancer; 2019 Sep; 135():161-168. PubMed ID: 31446990
[TBL] [Abstract][Full Text] [Related]
24. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer.
Lerouge D; Rivière A; Dansin E; Chouaid C; Dujon C; Schott R; Lavole A; Le Pennec V; Fabre E; Crequit J; Martin F; Dehette S; Fournel P; Precheur-Agulhon B; Lartigau E; Zalcman G
BMC Cancer; 2014 Mar; 14():231. PubMed ID: 24678902
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
Govindan R; Bogart J; Stinchcombe T; Wang X; Hodgson L; Kratzke R; Garst J; Brotherton T; Vokes EE
J Clin Oncol; 2011 Aug; 29(23):3120-5. PubMed ID: 21747084
[TBL] [Abstract][Full Text] [Related]
27. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.
Lu C; Lee JJ; Komaki R; Herbst RS; Feng L; Evans WK; Choy H; Desjardins P; Esparaz BT; Truong MT; Saxman S; Kelaghan J; Bleyer A; Fisch MJ
J Natl Cancer Inst; 2010 Jun; 102(12):859-65. PubMed ID: 20505152
[TBL] [Abstract][Full Text] [Related]
28. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
29. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma.
Li L; Li W; Wang C; Yan X; Wang Y; Niu C; Zhang X; Li M; Tian H; Yao C; Jin H; Han F; Xu D; Han W; Li D; Cui J
Cytotherapy; 2018 Jan; 20(1):134-148. PubMed ID: 29056549
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
[TBL] [Abstract][Full Text] [Related]
31. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
Peters S; Felip E; Dafni U; Tufman A; Guckenberger M; Álvarez R; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Lambrecht M; Andratschke N; Tsourti Z; Piguet AC; Roschitzki-Voser H; Gasca-Ruchti A; Vansteenkiste J; Stahel RA; De Ruysscher D
J Thorac Oncol; 2021 Feb; 16(2):278-288. PubMed ID: 33188912
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Seung SK; Ross HJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
[TBL] [Abstract][Full Text] [Related]
33. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
Spigel DR; Shipley DL; Waterhouse DM; Jones SF; Ward PJ; Shih KC; Hemphill B; McCleod M; Whorf RC; Page RD; Stilwill J; Mekhail T; Jacobs C; Burris HA; Hainsworth JD
Oncologist; 2019 Dec; 24(12):e1409-e1416. PubMed ID: 31420467
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer.
Choi MG; Kim YJ; Lee JC; Rho JK; Choi CM
Thorac Cancer; 2020 Nov; 11(11):3337-3345. PubMed ID: 33017518
[TBL] [Abstract][Full Text] [Related]
35. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.
Iliopoulou EG; Kountourakis P; Karamouzis MV; Doufexis D; Ardavanis A; Baxevanis CN; Rigatos G; Papamichail M; Perez SA
Cancer Immunol Immunother; 2010 Dec; 59(12):1781-9. PubMed ID: 20703455
[TBL] [Abstract][Full Text] [Related]
39. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
40. Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy.
Zhao Z; Liao H; Ju Y
J Tradit Chin Med; 2016 Feb; 36(1):14-8. PubMed ID: 26946613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
